4-antigen Staphylococcus aureus vaccine - Pfizer

Drug Profile

4-antigen Staphylococcus aureus vaccine - Pfizer

Alternative Names: PF-06290510; PF-6290510; Quadrivan; SA4Ag

Latest Information Update: 08 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Bacterial vaccines; Conjugate-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Staphylococcal infections

Most Recent Events

  • 21 Apr 2018 Immunogenicity and safety data from a phase II trial in Staphylococcal infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 01 Sep 2016 Pfizer completes a phase II trial in Staphylococcal infections (Prevention) in Japan (IM) (NCT02492958)
  • 07 Jul 2015 Phase-II clinical trials in Staphylococcal infections (Prevention) in Germany (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top